Wholeness of Life Awards for Compassionate Care

The Mount Sinai staff members honored were, from left, Raymond V. Wedderburn, MD; Lindsay Condrat, RN, MSN, ACNP-BC; and Junior Corniel.

Three Mount Sinai Health System employees received 2018 Wholeness of Life Awards from the HealthCare Chaplaincy Network™ for their commitment to providing compassionate and respectful care to patients. The staff members, all nominated by their colleagues, received their awards in November at the HealthCare Chaplaincy Network’s annual gala at the Lotte New York Palace.

Raymond V. Wedderburn, MD, FACS, Chief of Trauma and Critical Care at Mount Sinai St. Luke’s and Mount Sinai West, and Assistant Professor of Surgery, Icahn School of Medicine at Mount Sinai, was honored for being a gifted teacher and healer whose care for patients integrates mind, body, and spirit.

Lindsay Condrat, RN, MSN, ACNP-BC,Associate Director of Nursing, Mount Sinai Heart, was recognized for her personalized and holistic approach, especially in caring for patients who are far from home and families who are going through a difficult time.

Junior Corniel, an X-ray technician at Mount Sinai Beth Israel, was honored as an exceptionally empathic worker whose “love for his job and patients alike shines through every day.”

The HealthCare Chaplaincy Network is a global, nonprofit organization that offers spiritual care-related information and resources to hospitals and health care institutions.

STAT Online: Virtual Repurposing Can Speed the Discovery of New Uses for Existing Drugs

Inga Peter, PhD

In an essay in STAT, a leading online publication covering the life science industry, Inga Peter, PhD, Professor, Genetics and Genomic Sciences, at the Icahn School of Medicine at Mount Sinai, writes about a new approach to drug discovery—sometimes called virtual repurposing—that offers a way to discover unknown connections between “unconnected” diseases that may lead to new treatments.

Dr. Peter is a genetic epidemiologist with extensive experience designing studies aimed at identifying  genetic risk factors associated with complex diseases such as type 2 diabetes, obesity, cardiovascular disease, and Crohn’s disease.

Read the essay in STAT online

Learn more about the Peter Laboratory at the Icahn School of Medicine

Two Studies Point to the Quality of Neoantigens in Determining Long-Term Cancer Survival

Benjamin Greenbaum, PhD

The quality, not quantity, of tumor neoantigens may best predict a patient’s response to cancer immunotherapy and his or her chance of long-term survival. That finding was based on two groundbreaking studies co-authored by Benjamin Greenbaum, PhD, Assistant Professor, Medicine (Hematology and Medical Oncology), and Pathology, Icahn School of Medicine at Mount Sinai. Now, it is being further explored by Dr. Greenbaum and Vinod Balachandran, MD, Memorial Sloan Kettering Cancer Center, through a Stand Up to Cancer Convergence 2.0 Grant and funding from the Lustgarten Foundation.

Their goal is to understand the underpinnings of pancreatic cancer survivorship, and their team is one of seven research groups that comprise Stand Up to Cancer’s broad $11 million initiative that was announced in January 2018. Neoantigens, or peptides found on the surface of cancer cells, are considered promising targets for cancer immunotherapy.

“Previous research has shown that T cell immunity is linked to exceptional outcomes for the few long-term survivors of pancreatic cancer, but it wasn’t clear if neoantigens played a role,” says Dr. Greenbaum. “Our newest research shows there are particular neoantigens that seem to be driving this long-term response in patients with pancreatic cancer, and further suggests that targeting those neoantigens might be a viable therapeutic strategy.”

According to Dr. Greenbaum, who was trained as a physicist and quantitative biologist, “One of the most exciting aspects of our work is collaborating with academic teams that can combine the tools and knowledge from diverse fields like theoretical physics, structural biology, mathematics, computer science, and translational genomics. We never lose sight of the fact that our combined efforts could one day result in clinical breakthroughs that benefit countless numbers of people.”

Earlier research formed the basis of the team’s efforts. In the first of two back-to-back studies published in Nature (November 2017), researchers described a mathematical model they developed—the first of its kind—to predict how a cancer patient would benefit from certain immunotherapies. Dr. Greenbaum was the senior author on this work with first author Marta Luksza, PhD, Assistant Professor of Oncological Sciences, Icahn School of Medicine at Mount Sinai.

By capturing aspects of a tumor’s evolution and ways in which it interacted with the underlying immune system, the new model appeared to offer an approach beyond previous biomarkers. Going forward, it also has the potential to uncover new therapeutic targets within the immune system, and help in the design of vaccines for patients who do not respond to immunotherapy.

The second study, whose first author was Dr. Balachandran, applied the modeling framework in order to better understand immune response in patients with pancreatic cancer and, more specifically, the unique role of neoantigens.

As part of the broad initiative, the Mount Sinai researchers are focused on better understanding what makes a neoantigen a good immune target, and the role of the microbiome in neoantigen recognition. By advancing the core science behind developing a vaccine for pancreatic cancer, the research could eventually improve treatment prospects for patients with this deadly form of the disease.

As they investigate the immune system’s response to cancers, the Convergence 2.0 team will be encouraged to draw upon the knowledge of Microsoft Research experts in machine learning and artificial intelligence. In addition to Dr. Luksza, the research team includes Nina Bhardwaj, MD, PhD, from the Icahn School of Medicine at Mount Sinai; and Eileen M. O’Reilly, MD; Taha Merghoub, PhD; and Jedd D. Wolchok, MD, PhD, from Memorial Sloan Kettering Cancer Center.

Mount Sinai Doctors Long Island Celebrates New Location

From left: Kenneth L. Davis, MD; patient Elly Arabadjief with her mother, Tracy; father, Justin; and sister, Abigail; and Alicia Gresham, Vice President of Operations, Mount Sinai Health Network.

Mount Sinai Doctors Long Island is expanding its reach with the opening of a new health complex in Greenlawn to better serve the northwestern communities of Suffolk County. The modern and spacious 80,000-square-foot location, at 5 Cuba Hill Road, offers primary care, 20 medical and surgical specialties, a comprehensive Women’s Center, and an infusion center, as well as onsite radiology and laboratory services. The facility consolidates the Mount Sinai Doctors Long Island practices from three separate locations in Huntington.

A ribbon-cutting for the $22 million facility, developed in conjunction with Simone Healthcare Development Group, was held on Thursday, October 18, and was attended by about 100 guests, among them Mount Sinai executives and Long Island elected officials, including Hempstead Town Supervisor Chad Lupinacci, as well as physicians and managers from several Mount Sinai Doctors Long Island locations.

Patient Elly Arabadjief, with pediatric hepatologist Jaime Chu, MD.

“Residents of Long Island deserve high-quality, convenient care close to home, and Mount Sinai is meeting that need,” said Kenneth L. Davis, MD, President and Chief Executive Officer of the Mount Sinai Health System. “With an expanded primary and specialty care network and a Long Island footprint that includes 200 physicians and other experts at 11 multidisciplinary practice locations, Mount Sinai is transforming care in this area. Our goal is to keep patients and communities healthy by providing health care excellence close to home and work.”

At the new Cuba Hill Road facility, 70 board certified physicians working with nurses and other medical staff are providing primary care, as well as specialty care in allergy, asthma, and immunology; cardiology; dermatology; endocrinology; gastroenterology; hematology/oncology; nephrology; neurology; obstetrics and gynecology; ophthalmology; orthopedics; pain management; general pediatrics; pediatric gastroenterology; podiatry; pulmonology; rheumatology; surgery; and urology. For patients’ convenience, the office offers extended hours, ample parking, and comfortable waiting areas.

“Mount Sinai Doctors Long Island is expanding access to specialty care with a local state-of-the-art facility that will serve as a medical hub for this community,” said Arthur A. Klein, MD, President of the Mount Sinai Health Network. “Our physician partners will work collaboratively and tirelessly to provide personalized care for each patient. We are proud to bring the renowned services of Mount Sinai to serve the residents of Suffolk County and beyond.”

Guests gathered in the main waiting area of the new Mount Sinai Doctors Long Island location at 5 Cuba Hill Road in Greenlawn for the ribbon-cutting celebration.

A very special guest at the event was 8-year-old patient Elly Arabadjief. She and her family were honored for their efforts to raise awareness for Wilson disease, a rare inherited disorder that was diagnosed in Elly in August 2017 by her Mount Sinai Doctors Long Island pediatrician, Steven J. Brunner, MD. Elly’s father, Justin Arabadjief, gave an emotional speech as he expressed the family’s profound gratitude for Dr. Brunner’s astute diagnosis and credited him with saving his daughter’s life. Individuals with Wilson disease lack an enzyme, which causes copper to accumulate in the liver and other vital organs. The disease can be fatal if not discovered early.

Recalling the Wilson Disease Association conference he attended in 2018, Mr. Arabadjief said he met patients of all ages, at varying stages of their illness. “We heard horror stories of missed diagnoses, but we only met a small handful like Elly, who were lucky enough to have had this disease discovered early enough to have every chance at a long, happy, healthy life.”

Dr. Brunner said, “I always say pediatrics is not just about colds, coughs, and sore throats. There’s always that needle in the haystack that you have to be on the lookout for, and this case was definitely a needle in the haystack.”

It was Dr. Brunner who immediately referred Elly to Joanne Lai, MD, Assistant Professor of Pediatrics (Pediatric Gastroenterology), who is based in Manhattan and practices at Mount Sinai Doctors Long Island on a sessional basis, and to Jaime Chu, MD, Assistant Professor of Pediatrics (Pediatric Hepatology), who practices at Mount Sinai Kravis Children’s Hospital in Manhattan.

“We were fast-tracked with several specialists to review Elly’s symptoms and help with the diagnosis,” said Mr. Arabadjief. “We are thankful for all of the kind, compassionate people at various Mount Sinai locations we have met along the way to help get us through one of the scariest things that can happen to a family.”

 

From left: Jeffrey Vacirca, MD, Chief Executive Officer, New York Cancer & Blood Specialists; Kenneth L. Davis, MD; Arthur A. Klein, MD; Luis Isola, MD, Medical Director, Mount Sinai Cancer Network; and Benjamin Kornitzer, MD, Chief Medical Officer and Vice President, Mount Sinai Health Network.

Center to Enhance Clinical and Operational Outcomes

Attending the ribbon-cutting were, from left: Larry Attia, MD, Associate Medical Director for Clinical Informatics, Mount Sinai St. Luke’s and Mount Sinai West; family members Ela Navarro, Clara Jones, and Cody Jones; Arthur Gianelli, MBA, MPH; Timothy Day, Chief Operating Officer, Mount Sinai West; Peter and Bridget Jones, the parents of the late James P. Jones, MD; and Lucy Xenophon, MD, MPH.

Mount Sinai St. Luke’s celebrated the opening of The James P. Jones Daily Management and Incident Command Center on Wednesday, December 5, with a ribbon-cutting and dedication ceremony. James P. Jones, MD, who passed away unexpectedly in December 2016, served as Vice President of Administration for Mount Sinai West and Senior Medical Director of Clinical Documentation Quality Improvement for the Mount Sinai Health System.

With astounding energy and passion, he led collaborative efforts across the Health System to enhance clinical and operational outcomes at all levels of care.

“Dr. Jones’s commitment to enhancing patient care, experience, and outcomes was apparent throughout his 16-year career,” said Arthur A. Gianelli, MBA, MPH, President of Mount Sinai St. Luke’s. “We are honored to dedicate this Center to a wonderful friend, teacher, and colleague who touched the lives of so many of us.” At the ceremony were 140 Mount Sinai colleagues, friends, and family members, including Dr. Jones’s widow, Clara, and their son, Cody.

The late James P. Jones, MD

The Daily Management and Incident Command Center is the first of its kind in the Health System and was created in partnership with the Epic Clinical Transformation Group, the IT Program Management Office, and the Mount Sinai St. Luke’s Lean Team, an effort that also involved a number of other multidisciplinary groups. It was established to serve as a real-time operational monitoring hub for Mount Sinai St. Luke’s, with the goal of improving patient flow and daily hospital operations. It also is outfitted to act as an incident command center in times of hospital emergencies.

“The opening of this Center reflects the commitment and passion of many people throughout the Health System over the last 18 months to harness real-time hospital data to improve, on a daily basis, the way in which we deliver health care,” said Lucy Xenophon, MD, MPH, Chief Transformation Officer at Mount Sinai St. Luke’s and co-founder of the Center. “I can think of no other tribute to James that is more fitting to honor his legacy of intelligence, humor, respect, and courage to fight for continuous improvement.”

FREEDOM Follow-On Study Confirms Therapy for Patients With Diabetes and Heart Disease

Valentin Fuster, MD, PhD

A long-term international study led by researchers at Mount Sinai Heart is helping to establish an optimal standard of care for patients with diabetes and advanced multivessel coronary artery disease—a group at high risk for heart attack and stroke.

The FREEDOM Follow-On Study found that patients in this group who are treated with coronary artery bypass grafting (CABG) survive significantly longer than those treated with percutaneous coronary intervention (PCI) with drug-eluting stents.

Over a period of seven and one-half years, mortality from all causes was 18.7 percent for the CABG group and 23.7 percent for the PCI cohort. The study found that younger patients fared the best, with the difference most significant for those under age 63. “These data support current recommendations that CABG be considered the preferred strategy for patients with diabetes and multivessel disease,” says the study’s principal investigator, Valentin Fuster, MD, PhD, Director of Mount Sinai Heart, and Physician-in-Chief of The Mount Sinai Hospital.

During CABG, a healthy artery or vein from the body is connected, or grafted, to the blocked coronary artery, providing a bypass around the blocked portion of the coronary artery. In PCI—a minimally invasive procedure also known as angioplasty—a catheter is threaded through the body to a blocked or occluded vessel in the heart. The occlusion is removed and a drug-eluting stent is often inserted to maintain flow within the blood vessel.

The FREEDOM Follow-On Study, published in the Journal of the American College of Cardiology in November 2018, is the successor to the FREEDOM (Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease) trial, which randomized 1,900 patients with diabetes. That original study, which concluded in 2012, found that individuals who have diabetes and advanced coronary artery disease live longer and are less likely to suffer a nonfatal heart attack when treated with CABG instead of PCI with drug-eluting stents. The median follow-up time of that trial—just under four years—was considered relatively short, however, because of the prolonged nature of atherosclerotic cardiovascular disease.

Consequently, Mount Sinai developed a longer-term follow-up study, and 25 of the original international centers agreed to participate, tracking data on the mortality of 943 patients from the original FREEDOM trial. Adults with diabetes are two to four times more likely to die from heart disease than those without it, according to the American Heart Association.

In addition to confirming a standard of care for such patients, the study’s results underscore the importance of aggressive medical treatment and prevention to keep them from reaching advanced stages of diabetes, hypertension, and high cholesterol—forestalling the need for either CABG or PCI, Dr. Fuster says.

“We have to pay attention to how we can prevent this late stage of disease by taking care of obesity,” he says. “About 70 percent of these patients were obese, and we can do a lot to prevent this.”